Targeting Mast Cell Activation and MIF‐Mediated Remodelling Enhances Chemotherapy Response in Pancreatic Cancer

mice or pharmacologic stabilization using sodium cromoglycate and the MIF antagonist ISO-1 synergistically improves AG efficacy, with further benefit observed upon addition of anti-PD-1 therapy. These findings reveal a previously unrecognized mechanism of AG therapy-induced immunosuppression and nominate TAMCs-MIF signaling as a tractable target to optimize neoadjuvant strategies in PDAC.